Should You Buy TELA Bio Inc (TELA) Today? Analysis, Price Targets, and 2026 Outlook.
Conclusion
Hold
Latest Price
0.960
1 Day change
-2.14%
52 Week Range
2.960
Analysis Updated At
2026/01/26
TELA Bio Inc is not a strong buy for a beginner, long-term investor with $50,000-$100,000 available for investment. The stock's technical indicators are bearish, financial performance is weak with declining net income and EPS, and analysts have significantly lowered price targets due to disappointing Q3 results. While options data shows low put-call ratios, indicating some bullish sentiment, the lack of strong positive catalysts and the absence of Intellectia Proprietary Trading Signals suggest holding off on investing in this stock at this time.
Technical Analysis
The technical indicators for TELA are bearish. The MACD is below 0 and negatively contracting, the RSI is neutral at 38.606, and the moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). Key support levels are at 0.947 and 0.902, with resistance levels at 1.092 and 1.137.
Options Data
Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio
The open interest put-call ratio is very low at 0.03, and the option volume put-call ratio is 0.0, indicating a lack of bearish sentiment in options trading. However, the implied volatility is high, with an IV percentile of 98.8 and an IV rank of 100, suggesting significant uncertainty.
Technical Summary
Sell
10
Buy
2
Positive Catalysts
2026/01/26 05:59:15
Options data shows low put-call ratios, indicating some bullish sentiment. Additionally, revenue increased by 9.14% YoY in Q3 2025.
Neutral/Negative Catalysts
2026/01/26 05:59:15
Analysts have significantly lowered price targets due to disappointing Q3 results, including missed revenue expectations and lowered full-year guidance. Net income and EPS have declined sharply YoY, and gross margin has slightly decreased. Technical indicators are bearish, and there are no recent news or congress trading data to suggest a positive catalyst.
Financial Performance
In Q3 2025, revenue increased by 9.14% YoY to $20,689,000. However, net income dropped by 17.06% YoY to -$8,603,000, and EPS declined by 54.76% YoY to -0.19. Gross margin slightly decreased to 67.52%, down 0.46% YoY, indicating weakening profitability.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Analysts have lowered their price targets significantly. Canaccord reduced the target to $4 from $7 while maintaining a Buy rating. Citizens JMP lowered the target to $5 from $7 with an Outperform rating. Piper Sandler reduced the target to $1.25 from $2 and maintained a Neutral rating. Analysts cite disappointing Q3 results, missed revenue expectations, and lowered guidance as key concerns.
Wall Street analysts forecast TELA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TELA is 3.31 USD with a low forecast of 1.25 USD and a high forecast of 5 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
Wall Street analysts forecast TELA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TELA is 3.31 USD with a low forecast of 1.25 USD and a high forecast of 5 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 0.980
Low
1.25
Averages
3.31
High
5
Current: 0.980
Low
1.25
Averages
3.31
High
5
Canaccord
Buy
downgrade
$7 -> $4
AI Analysis
2025-11-18
Reason
Canaccord
Price Target
$7 -> $4
AI Analysis
2025-11-18
downgrade
Buy
Reason
Canaccord lowered the firm's price target on Tela Bio (TELA) to $4 from $7 and keeps a Buy rating on the shares. The firm said they posted a challenged Q3 as it missed top-line expectations and lowered full-year guidance, though it reiterated confidence in its commercial strategy and sales force structure as recent hires Jeffrey Blizzard and Jim Hagen from Abiomed (ABMD) become increasingly important pieces to the Tela Bio story.
Citizens JMP
Outperform
to
NULL
downgrade
$7 -> $5
2025-11-14
Reason
Citizens JMP
Price Target
$7 -> $5
2025-11-14
downgrade
Outperform
to
NULL
Reason
Citizens JMP lowered the firm's price target on Tela Bio to $5 from $7 and keeps an Outperform rating on the shares. Quarterly sales were shy of the Street by about 5%, reflecting several meaningful highlights, such as strong international sales and the addition of new customers, the analyst tells investors in a research note. The cons outweighed the pros, and management lowered its top-line guidance by 9% year over year, the firm adds.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for TELA
